Lloyd Tran, PhD
Biomed Industries, Inc.
6
1
3
N/A
0
5
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+19 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (6)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Sabine Hazan, MD
ProgenaBiome
Shared therapeutic areas:
David Crowley, MD
KGK Science Inc.
Shared therapeutic areas:
Samuel Klein, MD
Washington University School of Medicine
Shared therapeutic areas:
Ali MA Ismail, lecturer
Cairo University
Shared therapeutic areas:
ali ismail, lecturer
Cairo University
Shared therapeutic areas:
Meral Boşnak Güçlü, Prof. Dr.
Gazi University
Shared therapeutic areas:
Melda Saglam, PhD
Hacettepe University
Shared therapeutic areas:
Andrea Natale, MD
Texas Cardiac Arrhythmia Research Foundation
Shared therapeutic areas:
Shirley Wang, PhD, ScM
Brigham and Women's Hospital
Shared therapeutic areas:
Anissa MEGZARI
Centre Hospitalier Universitaire de Nīmes
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (6)
Showing 6 of 6 trials
Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid Condition
Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus
A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831
NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection
Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831
Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese
All 6 trials loaded